- Home
- UBFO vs CNTX Comparison
UBFO vs CNTX Comparison
Compare UBFO & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBFO
- CNTX
- Stock Information
- Founded
- UBFO 1987
- CNTX 2015
- Country
- UBFO United States
- CNTX United States
- Employees
- UBFO N/A
- CNTX N/A
- Industry
- UBFO Major Banks
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- UBFO Finance
- CNTX Health Care
- Exchange
- UBFO Nasdaq
- CNTX Nasdaq
- Market Cap
- UBFO 141.0M
- CNTX 149.6M
- IPO Year
- UBFO N/A
- CNTX 2021
- Fundamental
- Price
- UBFO $9.50
- CNTX $1.84
- Analyst Decision
- UBFO
- CNTX Strong Buy
- Analyst Count
- UBFO 0
- CNTX 3
- Target Price
- UBFO N/A
- CNTX $6.83
- AVG Volume (30 Days)
- UBFO 28.5K
- CNTX 318.3K
- Earning Date
- UBFO 10-18-2024
- CNTX 11-06-2024
- Dividend Yield
- UBFO 5.04%
- CNTX N/A
- EPS Growth
- UBFO N/A
- CNTX N/A
- EPS
- UBFO 1.03
- CNTX N/A
- Revenue
- UBFO $51,962,000.00
- CNTX N/A
- Revenue This Year
- UBFO N/A
- CNTX N/A
- Revenue Next Year
- UBFO N/A
- CNTX N/A
- P/E Ratio
- UBFO $9.25
- CNTX N/A
- Revenue Growth
- UBFO N/A
- CNTX N/A
- 52 Week Low
- UBFO $7.02
- CNTX $0.77
- 52 Week High
- UBFO $9.60
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- UBFO 72.66
- CNTX 37.02
- Support Level
- UBFO $9.28
- CNTX $1.90
- Resistance Level
- UBFO $9.51
- CNTX $2.32
- Average True Range (ATR)
- UBFO 0.20
- CNTX 0.14
- MACD
- UBFO 0.05
- CNTX -0.04
- Stochastic Oscillator
- UBFO 93.20
- CNTX 9.80
About UBFO United Security Bancshares
United Security Bancshares operates as the holding for United Security Bank. It provides commercial banking services to the business and professional community, and individuals located in Fresno, Madera, Santa Clara, and Kern Counties. It offers checking and savings accounts, deposits, mortgage loans, credit and debit cards, safe deposit boxes, automated teller machines, wire transfers, money market accounts, mobile banking, and wealth management services. The company's primary sources of revenue are interest income from loans and investment securities.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.